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Abstract
Background: Osteogenesis Imperfecta (OI) is a heritable connective tissue disorder mainly caused by mutations in
the genes COL1A1 and COL1A2 and is associated with hearing loss in approximately half of the cases. The hearing
impairment usually starts between the second and fourth decade of life as a conductive hearing loss, frequently
evolving to mixed hearing loss thereafter. A minority of patients develop pure sensorineural hearing loss. The
interindividual variability in the audiological characteristics of the hearing loss is unexplained.
Methods: With the purpose of evaluating inter- and intrafamilial variability, hearing was thorougly examined in 184
OI patients (type I: 154; type III: 4; type IV: 26), aged 3-89 years, with a mutation in either COL1A1 or COL1A2 and
originating from 89 different families. Due to the adult onset of hearing loss in OI, correlations between the
presence and/or characteristics of the hearing loss and the underlying mutation were investigated in a subsample
of 114 OI patients from 64 different families who were older than 40 years of age or had developed hearing loss
before the age of 40.
Results: Hearing loss was diagnosed in 48.4% of the total sample of OI ears with increasing prevalence in the
older age groups. The predominant type was a mixed hearing loss (27.5%). A minority presented a pure
conductive (8.4%) or pure sensorineural (12.5%) loss. In the subsample of 114 OI subjects, no association was found
between the nature of the mutation in COL1A1 or COL1A2 genes and the occurrence, type or severity of hearing
loss. Relatives originating from the same family differed in audiological features, which may partially be attributed
to their dissimilar age.
Conclusions: Our study confirms that hearing loss in OI shows a strong intrafamilial variability. Additional
modifications in other genes are assumed to be responsible for the expression of hearing loss in OI.
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1. Background
Osteogenesis imperfecta (OI) is a hereditary connective
tissue disorder, clinically characterized by a variable degree
of bone fragility with recurrent fractures, scoliosis, bone
deformities, and short stature as well as non-skeletal
abnormalities including blue sclerae, abnormal dentition,
and joint hyperlaxity. Hearing loss is a common problem
in patients with OI caused by type I (pro)collagen defects.
On the basis of clinical and radiographic features, Sillence
and colleagues [1] distinguished 4 OI subtypes, each repre-
senting a different phenotype with a mild (I), lethal (II),
severe (III), and moderate (IV) severity. In most cases, the
genotype is characterized by a heterozygous mutation in
either the COL1A1 or COL1A2 gene. More uncommon,
autosomal recessive forms caused by mutations in other
genes have recently been discovered, but have not been
associated with hearing loss. The genes COL1A1 and
COL1A2 are both responsible for the formation of type I
collagen, the major structural protein of bone, sclerae, liga-
ments, and tendons. Different mutation types may lead to
various OI phenotypes. Nonsense, frameshift, and some
splice site mutations result in a reduced synthesis of
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structurally normal type I collagen, also referred to as hap-
loinsufficiency or a quantitative defect, and usually cause
milder phenotypes (OI type I). In the more severe OI
types (II-IV), mutations affect the structure of either the
proa1(I) or proa2(I) chain and lead to the production of
qualitatively abnormal collagen molecules. Glycine substi-
tutions in the triple helical domain are the most common,
but some splice site mutations leading to in-frame exon
skips may also induce structurally impaired type I col-
lagen. This group of mutations has a negative dominant
effect. The overall clinical outcome depends on the type of
impairment of type I collagen synthesis (quantitative or
qualitative), the mutated gene, the substituting amino acid,
and the location of the mutation in the triple helical
domain [2,3]. However, genotype-phenotype correlation
studies have not been straightforward and inter- and intra-
familial variability in clinical characteristics partially
remain unresolved [4].
The variability of the OI phenotype is also observed for
the hearing loss and has long been a matter of study and
debate. A variable prevalence of hearing loss in OI from
37 to 64% has been reported in family studies [5-11] and
from 45 to 58% in nationwide population studies with sys-
tematic audiological evaluation [12-15]. In general, hearing
loss in OI is believed to develop bilaterally as mild conduc-
tive hearing loss in the second to fourth decade of life,
subsequently progressing to a mixed hearing loss with a
severity ranging from mild to profound [8,10,13-17] Pure
sensorineural hearing loss has been observed in a minority
of OI patients.[8,13,15-17]. Like the majority of the charac-
teristics inherent to the disease, OI-related hearing loss is
apparently heterogeneous in occurrence, type, progression,
severity, and underlying pathology. Although it has been
suspected to be associated with a COL1A1 mutation [18]
and to predominantly occur in the milder OI types [1,19],
no association has been demonstrated between the pre-
sence and type of hearing loss, and the OI subtype, the
mutated gene or mutation type in a Finnish population of
47 unrelated OI patients with identified mutations in
COL1A1 or COL1A2[20].
In the present study, audiological and genotypic charac-
teristics as well as potential environmental risk factors for
the development of hearing loss are investigated in a
cohort of Belgian, Dutch, and Italian OI patients with
familial or sporadic OI. In addition, inter- and intrafamilial
variability in audiological features are studied.
2. Methods
2.1 Study subjects
In the period 2008 - 2010, a total number of 184 (89
male; 95 female) of whom 86 Belgian, 67 Dutch, and 31
Italian OI patients participated in this study. They origi-
nated from 89 independent families (43 Belgian; 25
Dutch; 21 Italian). The study was approved by the Ethical
Committees of the Ghent University Hospital (UZ
Ghent), the Radboud University Nijmegen Medical Cen-
tre (UMCN), and the Rizzoli Orthopaedic Institute (ROI)
of Bologna. According to the Declaration of Helsinki,
informed consent was obtained in each patient prior to
participation. In Belgium, patients were recruited at the
departments of Otorhinolaryngology, Medical Genetics,
Orthopedics, and Rheumatology & Endocrinology of the
UZ Ghent and by an advertisement in the periodical dis-
tributed by the Belgian patients’ association for OI (Zelf-
hulp Osteogenesis Imperfecta). Dutch and Italian OI
patients were informed about this study and invited to
participate by their otorhinolaryngologists attached to
the UMCN and the pediatric clinic of the La Sapienza
University of Rome, respectively. All participants had a
clinical diagnosis of OI and were examined at the depart-
ments of Otorhinolaryngology of the UZ Ghent, UMCN
or the pediatric clinic of the La Sapienza University of
Rome.
Audiological and molecular data were obtained in the
184 subjects, all of which are analyzed and presented in
this paper. Correlation analysis between audiological
phenotype and genotype was, due to the adult onset of
hearing loss in OI, which is demonstrated below, per-
formed on a subsample of 114 OI patients, hereinafter
called the ‘selected sample’. The latter consisted of the
normal-hearing OI patients older than 40 years and the
patients diagnosed with hearing loss at any age.
2.2 History and clinical examination
The patients’ medical histories and otological complaints
were listed. They were interviewed about medication,
noise exposure, family history of OI and hearing loss,
subjective onset of hearing loss, use of hearing aids, pre-
vious ear surgery, head injury, and middle ear infections.
Micro-otoscopy was performed by an otorhinolaryn-
gologist. The clinical OI subtype was assessed by a
geneticist.
2.3 Audiometry
Pure-tone audiometry was performed in a double-walled
sound-attenuated room. Applying the modified Hugh-
son-Westlake method, air conduction (AC) thresholds
were bilaterally determined at octave frequencies 0.25 -
8.0 kHz and at half-octave frequencies 3.0 and 6.0 kHz,
as well as bone conduction (BC) thresholds at octave-
frequencies 0.25 - 4.0 kHz and half-octave frequency 3.0
kHz (AC 40 Clinical Audiometer, Interacoustics, Assens,
Denmark). Masking noise was presented at the contral-
ateral ear through a headphone to assess masked AC
and BC thresholds according to Hood’s plateau method,
when interaural differences in AC or intra-aural air-
bone gap (ABG) were beyond 40 dB and 10 dB,
respectively.
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Normal hearing corresponded to AC thresholds < 15 dB
HL averaged over 0.5, 1.0, and 2.0 kHz. Hearing loss was
classified as (1) conductive: BC thresholds < 15 dB HL and
ABG ≥ 15 dB averaged over 0.5, 1.0, and 2.0 kHz; (2) pure
sensorineural: AC thresholds ≥ 15 dB HL and ABG < 15
dB averaged over 0.5, 1.0, and 2.0 kHz or AC thresholds >
30 dB HL averaged over 4.0, 6.0, and 8.0 kHz; and (3)
mixed: BC thresholds ≥ 15 dB HL and ABG ≥ 15 dB aver-
aged over 0.5, 1.0, and 2.0 kHz. Hearing loss was substan-
tiated by comparison with the 95th percentile value for
sex- and age-related hearing thresholds [21]. Concretely, if
application of the above-mentioned definitions pointed
toward a hearing loss, the patient’s audiogram was com-
pared with the 95th percentile threshold values corre-
sponding to the patient’s age and sex. When the AC
thresholds of the patient exceeded those corresponding to
the 95th percentile values, the presence of hearing loss was
confirmed. When the AC thresholds from the patient’s
audiogram fell within the thresholds corresponding to the
95th percentile normal values, the diagnosis of hearing loss
was rejected and the patient was classified as ‘normal
hearing’.
In patients with previous middle ear surgery or cochlear
implantation, the preoperative audiometric data were
retrieved and included for analysis instead of their
recorded postoperative hearing thresholds.
2.4 Molecular-genetic analysis
Genomic deoxyribonucleic acid (DNA) was extracted from
ethylenediaminetetra-acetic (EDTA) blood samples
obtained by standard procedures in all subjects. The meth-
ods applied for mutation screening differed somewhat
between the Center for Medical Genetics Ghent (Belgian
and Dutch patients) and the ROI (Italian patients). In the
Dutch and Belgian probands, mutation screening of the
COL1A1 gene was initiated by polymerase chain reaction
(PCR) amplification of the 52 COL1A1 exons, using for-
ward and reverse primers. The PCR products were ana-
lyzed by gel electrophoresis using the Labchip GX Caliper,
software version 2.1.322.0 (Caliper Life Sciences, Hopkin-
ton, MA). All fragments were directly sequenced using the
ABI PRISM 3730XL automated sequencer (Applied Bio-
systems, Foster city, CA). In the Italian probands, com-
plete mutational screening of COL1A1 coding regions and
exon-intron junctions was performed on DNA by analyz-
ing samples with denaturing high pressure liquid chroma-
tography (DHPLC) followed by direct sequencing of
samples with abnormal elution profile. The coding exons
of COL1A1, along with exon-intron junctions, were PCR-
amplified. The results of amplification and the presence of
well-sized PCR reaction products were analyzed by gel
electrophoresis and visualized by ethidium bromide stain-
ing on 2% agarose gels. DHPLC analysis was carried out
using the WAVE DNA Fragment Analysis System
3500HT (Transgenomic, Crewe, UK) equipped with a
DNASep column (Transgenomic, Crewe, UK). Amplifica-
tion products showing abnormal elution profiles were
reamplified, purified with ExoSAP-IT (USB, Affymetrix,
Santa Clara, CA, USA) and sequenced in both forward
and reverse direction using BigDye Terminator chemistry
version 3.1 and ABI PRISM 3100 automated DNA sequen-
cer (Applied Biosystems, Foster City, CA, USA). Indepen-
dently of the sequencing method applied, the obtained
sequences for all COL1A1 exons were compared to the
wild-type sequences [GenBank:NG_007400.1] [22]. If no
causal mutation could be detected in any exon of the
COL1A1 gene, the appropiate procedure of those
described above was repeated for the proband’s 52
COL1A2 exons, using the wild-type reference sequences
[GenBank:NG_007405.1][22]. Presence of the mutation
identified in a proband was subsequently analyzed in all
participating relatives by PCR-amplification and sequen-
cing of the corresponding mutated exon in the COL1A1
or COL1A2 gene.
The outcomes of any previous biochemical analysis on
skin fibroblasts or COL1A1 null allele tests were retrieved
in the concerned medical center and compared to the cur-
rently obtained results from molecular-genetic analysis.
2.5 Statistical analysis
All data were entered into SPSS for statistical analysis
(SPSS Inc., Chicago, IL, USA). Quantitative parameters
were evaluated for normal distribution by means of the
Kolmogorov-Smirnov test. Associations between dichoto-
mous variables were verified using Chi-square or Fisher’s
exact test, if appropriate. Differences between median
values of two or more independent, quantitative, non-
normally distributed variables were evaluated with the
Mann-Whitney and Kruskal-Wallis tests, respectively. A
5% significance level was used throughout all analyses.
3. Results
3.1 Subjects and demographics
Sixty-eight out of the 89 probands reported a positive
family history for OI and from 39 of them, one to maxi-
mally six affected relatives participated in the study. A
sporadic form of OI was noted in 21 probands.
The majority of the 184 patients were diagnosed as OI
type I (83.7%). The remaining patients exhibited OI types
III (2.2%) and IV (14.1%). Mean age of the patients at
audiometric evaluation was 30.5 years (SD: 17.2; range 3-
89 years).
3.2 General otologic features and audiometric evaluation
Subjective hearing loss was reported by 50.0% of the 184
participants. Hearing amplification was used by 21.2% of
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the total sample of patients, of whom 87.2% wore hear-
ing aids, 10.3% was equipped with a cochlear implant,
and 2.5% had a bone-anchored hearing aid.
The total sample of 184 participants implied 89 pro-
bands. Out of these probands, 66.3% reported a positive
family history for hearing loss, which referred to either
hearing loss in relatives affected with OI (64.0%) or
presbyacusis in unaffected relatives of advanced age
(2.3%). In none of them, any other genetic cause for
familial hearing loss was suspected.
Audiometric evaluation revealed that 52.7% of the
examined OI patients exhibited a unilateral (8.7%) or
bilateral (44.0%) hearing loss, resulting into a 48.4% pre-
valence hearing impairment in the total number of 368
OI ears. Figure 1 presents the proportions of hearing-
impaired ears and the different types of hearing loss as a
function of age, the latter classified into decades. Five
ears of patients in the older age categories demonstrated
total deafness. Retrieval of audiometric history revealed
that progressive mixed hearing loss had preceded the
deafness in all cases.
The overall median age at onset of the hearing loss
as reported by the patients was 20 years (range: 5-60
years). Pure sensorineural hearing loss was character-
ized by a significantly later median onset (36.5 y.;
range: 10-60 y.) compared to conductive or mixed
hearing loss (19.0 y.; range: 5-42 y.) (Mann-Whitney
test; P < 0.001).
In 14.8% of the patients with bilateral hearing loss,
audiograms from left and right ears were asymmetric. In
the patients with unilateral hearing impairment, pure
conductive (n = 4), mixed (n = 4), and pure sensori-
neural hearing losses (n = 8) were observed.
3.3 Environmental risk factors for hearing loss
On the basis of a thorough history, a potential risk for
noise-induced hearing loss was noted in a total number
of 22 OI patients (12.0%), of whom five demonstrated
bilaterally normal hearing. Two patients reporting noise
exposure exhibited pure sensorineural hearing loss bilat-
erally. The remaining 15 patients had conductive or
mixed hearing loss.
A total number of nine patients (4.9%) had sustained a
skull fracture, one of whom exhibited unilaterally con-
ductive, and three bilaterally mixed hearing loss. The
remaining five patients had bilaterally normal hearing.
None of the patients with skull fractures attributed
development or deterioration of their hearing loss to the
trauma.
3.4 Molecular-genetic findings
Molecular-genetic screening of the 89 probands identi-
fied 69 COL1A1 (77.5%) and 20 COL1A2 (22.5%) muta-
tions. In the probands with a COL1A1 mutation we
found nonsense (n = 12), frameshift (n = 29), and splice
site (n = 21) mutations, as well as glycine substitutions
Figure 1 Prevalence and type of hearing loss as a function of age in 368 ears from 184 osteogenesis imperfecta patients. The
percentages of ears demonstrating conductive hearing loss (C HL), mixed hearing loss (M HL), pure sensorineural hearing loss (SNHL) or total
deafness are displayed for seven different age categories. For each age category, the corresponding number of ears is indicated (n).
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(n = 7). Splice site mutations (n = 2) and glycine substi-
tutions (n = 18) were observed in the probands with a
mutation in the COL1A2 gene. The retrieved results of
previous biochemical and COL1A1 null allele tests car-
ried out on the probands’ fibroblasts, confirmed a struc-
tural defect of type I collagen for one splice site
mutation, and haploinsufficiency of type I collagen for
11 other splice site mutations. The quantitative either
qualitative effects of the splice site mutations on type I
collagen synthesis was not determined in 10 probands,
in whom biochemical tests had not been performed pre-
viously and skin fibroblasts were not obtained.
The mutations were confirmed in all the probands’
participating affected relatives, resulting in a total num-
ber of 150 OI patients with COL1A1 (81.5%) and 34 OI
patients with COL1A2 mutations (18.5%).
3.5 Associations between genotype and audiological
phenotype in a selected sample of 114 OI patients
For the investigation of potential associations between
hearing loss and the underlying genotypic characteristics,
only the subjects older than 40 years or those that already
had developed hearing loss before 40 years of age were
included. This cut-off age was introduced on the basis of
the hearing loss onset, which was situated before the age
of 40 years in 90.8% of all hearing losses, and in 98.4% of
the hearing losses with a conductive component. Two
patients meeting these criteria were excluded because of
pure sensorineural loss that was probably due to noise
exposure. The selected 114 subjects, called ‘the selected
sample’, are listed per family (N = 64) including charac-
teristics of hearing and genotype (see additional file 1:
Audiological and molecular-genetic findings in the
selected sample of 114 osteogenesis imperfecta patients).
The investigation of the intrafamilial variability was
based on the 26 families from the 64 families in the
selected sample with two or more participating relatives.
3.5.1. Audiological findings in the selected sample
From the 114 patients in the selected sample, only 19
subjects demonstrated bilaterally normal hearing (16.7%).
The remaining 95 subjects had hearing loss in one
(12.2%) or both ears (71.1%). Of the total number of 228
ears in the selected sample, 54 ears presented normal
hearing (23.7%), whereas 31 ears were diagnosed with
pure conductive loss (13.6%), 101 ears with mixed hear-
ing loss (44.3%), and 42 with ears pure sensorineural
hearing loss (18.4%).
3.5.2. Molecular-genetic findings in the selected sample
A mutation in COL1A1 was identified in 51 out of the 64
probands (79.7%) included in the selected sample. The
mutational event was located in the COL1A2 gene in 13
other probands (20.3%). In 40/64 probands, the mutation
caused haploinsufficiency of type I collagen (62.5%),
whereas a structural type I collagen defect was encoun-
tered in 17 probands (26.6%). In 7 probands affected by
splice site mutations (10.9%), the either quantitative or
qualitative type I collagen defect was not determined due
to the lack of skin fibroblasts and biochemical tests.
3.5.3. Interfamilial variability
In only eight out of the 64 families from the selected
sample, none of the participating affected relatives
demonstrated hearing loss (12.5%). In six of these
families, quantitatively impaired type I collagen synthesis
was caused by a mutation in the triple helical domain of
the proa1(I) chain, whereas in the other two families a
qualitative defect due to a mutation in the triple helical
domain of the proa2(I) chain was found. In the remain-
ing 56 families from the selected sample (87.5%), conduc-
tive/mixed (44/64 or 68.8%) and/or pure sensorineural
hearing loss (20/64 or 31.2%) occurred in at least one
affected relative. Conductive/mixed hearing loss occurred
in OI families with mutations leading to quantitative type
I collagen defect that were located in the N-terminal pro-
peptide (n = 1), C-terminal propeptide (n = 2), and the
triple helical domain (n = 25) of the proa1(I) chain, as
well as in OI families with qualitatively impaired type I
collagen caused by mutations located in the triple helical
domain of the proa1(I) chain (n = 5) or the proa2(I)
chain (n = 4). In seven families with COL1A1 splice site
mutations of which the effect on type I collagen was
undetermined, conductive/mixed hearing loss was also
found. Pure sensorineural hearing loss was observed in
families in which OI was associated with haploinsuffi-
ciency of type I collagen due to a mutation in the triple
helical domain (n = 12) or the C-terminal propeptide
(n = 2) of the proa1(I) chain, and in families with a struc-
tural type I collagen defect due to a mutation in the triple
helical domain of the proa1(I) (n = 1) or proa2(I) chain
(n = 5). This hearing loss type was also diagnosed in
three families with splice site mutations located in the tri-
ple helical domains of the proa1(I) chain (n = 2), of
which the type I collagen defect was unknown. Applica-
tion of Chi-square and Fisher’s exact test could not
demonstrate that development of hearing loss and the
type of hearing loss in OI patients were dependent of the
mutated gene, the effect of the mutation on type I col-
lagen synthesis or the location of the mutation within the
proa chains.
3.5.4. Intrafamilial variability
Investigation of the intrafamilial variability in 26 families
from the selected sample with two to maximally five
affected relatives revealed that OI relatives with an identi-
cal mutation in COL1A1 or COL1A2 demonstrated het-
erogeneous hearing characteristics. In some families,
subjects with conductive or mixed hearing loss had rela-
tives with pure sensorineural hearing loss. Additionally,
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patients with conductive, mixed or pure sensorineural
hearing loss had normal-hearing affected relatives. In
contrast, in a number of families, certain correspondence
was observed with respect to the presence of a conduc-
tive or sensorineural component in at least one ear of
two or more relatives. The presence of a conductive com-
ponent in at least one ear of two related subjects was
seen in 18/26 families (69.2%) (families Nos. 2, 5, 7, 9, 12,
18, 24, 25, 26, 27, 28, 29, 30, 34, 38, 39, 40, and 54). Like-
wise, 18/26 families (69.2%) implicated at least two rela-
tives with a sensorineural hearing loss component in one
or both ears (families Nos. 2, 5, 7, 8, 9, 12, 15, 20, 25, 26,
27, 28, 29, 30, 37, 38, 39, and 40). Pure sensorineural
hearing loss affecting two relatives from the same family
was only seen in 4/26 families (15.4%) (families Nos. 8,
20, 26, and 37). A hearing loss with conductive compo-
nent in all participating relatives was noted in 11 differ-
ent families. In only one family with two or more
participants, all relatives demonstrated bilaterally normal
hearing (family No. 10). Furthermore, our selected sam-
ple included unrelated families that were sometimes
affected by the same mutation. This applied to three dif-
ferent mutations, which were each found in two unre-
lated families (COL1A2, c.1009G > A in families Nos. 1
and 19; COL1A1, c.1299+1G > A in families Nos. 44 and
50; and COL1A1, c.769G > A in families Nos. 7 and 22).
However, the subjects from two families affected by the
same mutation demonstrated incongruous audiometric
results. In contrast, all relatives from three unrelated
families affected by the same underlying COL1A1 muta-
tion (c.769G > A) were diagnosed with a hearing loss
characterized by a conductive component (families Nos.
5, 17, and 54).
3.5.5. Analysis of risk factors for hearing loss in the selected
sample
Finally, the selected sample was investigated for asso-
ciations between hearing loss and positive history for
otitis media, skull fracture or noise exposure. Although
25 out 27 of the OI patients with a history of recurrent
otitis media currently demonstrated hearing loss
(92.6%), the latter was not associated with a positive
history of otitis media, because 70 of the 95 hearing-
impaired OI patients did not report any episode of oti-
tis media (73.7%) (Chi-square test). Five patients had
sustained a skull fracture, of whom one presented
bilaterally normal hearing, one unilaterally pure sen-
sorineural loss, and three bilaterally mixed or conduc-
tive hearing loss. Noise exposure was confirmed by 14
subjects with mixed hearing loss and three normal-
hearing patients. The results of Fisher’s exact test were
not indicative for significant associations between a
history of noise exposure or a skull fracture and the
development of hearing loss.
4. Discussion
4.1 Audiological characteristics
Hearing loss deserves attention in patients with OI,
especially since its development, the age at onset, as
well as the progression and site of lesion seem difficult
to predict on the basis of genotype or hearing character-
istics in affected relatives. The prevalence of OI patients
affected by hearing loss in the present study amounted
to 52.7%. Although a certain selection bias in favour of
hearing loss cannot be ruled out, this value approxi-
mates the prevalence values established in other family
and population studies [5-10,13-15,17,23]. Though, the
number of hearing-impaired patients has been assumed
to grow with increasing age, reaching almost 100% in
the age group older than 60 years in some studies
[10,14-16]. We noted that in the patient group over 60
years of age, 77.3% of subjects bilaterally demonstrate
hearing thresholds exceeding the 95th percentile of age-
and sex-related thresholds in the healthy population,
whereas under 30 years of age less than 50% of the OI
subjects presented hearing loss.
Most authors agree that the majority of OI patients
initially develop a conductive loss in the second to fourth
decade of life which gradually progresses to a mixed
hearing loss [13-17]. Mixed hearing loss was the predo-
minant hearing loss type in the current study-population.
Pure conductive loss only occurred in patients under 40
years of age. This hearing loss has often been attributed
to an otosclerosis-like pathology involving stapes foot-
plate fixation and diffuse otosclerotic foci in the temporal
bone. In addition, ossicular discontinuity, most often
caused by atrophic or fractured crura, may be responsible
for conductive hearing loss in OI [10,14,16].
Pure sensorineural loss has been described to occur in
smaller but almost constant proportions in all age groups
[8,13,15,16]. The sensorineural component in OI has
been attributed to atrophy of the cochlear hair cells and
the stria vascularis, hemorrhage into the perilymph,
microfractures, otosclerotic bone encroaching on the otic
capsule, and membrane distortions [11,24].
The hearing loss commonly develops bilaterally and
symmetrically, independently of the type of hearing loss
involved. Conductive and mixed losses are most often
reported to start in the second decade whereas the
onset of pure sensorineural loss may be situated at any
age.
4.2 Associations between hearing loss and genotype
Although hearing loss has been suggested to occur pre-
dominantly in OI type I [1], this was not supported by a
Finnish population study [13] in which no correlation
was found between the OI subtype and the frequency or
severity of hearing loss. Our results reflected hearing
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loss to be a clinical manifestation in OI type I as well as
types III and IV. Because of the small number of type
III and type IV subjects included, no conclusions can be
drawn for associated hearing loss with a specific OI
type.
In the study by Hartikka et al.[20], in which audiometric
evaluation was accomplished in 49 unrelated OI patients
with identified mutations in the COL1A1 or COL1A2
gene, no correlation was found between the mutated gene,
the mutation type or type I collagen defect and the pre-
sence, type or severity of hearing loss. Consistently, the
present study fails in its effort to interrelate the audiologi-
cal phenotype from 114 OI patients originating from 64
distinct families with the underlying OI genotype. In
87.5% of the OI families, OI-related hearing loss of the
conductive/mixed or pure sensorineural type is observed
in at least one relative. Hearing loss affects both patients
with familial OI and sporadic OI. We noted intrafamilial
variability in hearing characteristics, with relatives sustain-
ing different types of hearing loss. Neither the mutated
gene, the quantitatively either qualitatively impaired type I
collagen or the location of the mutation with respect to
the triple helix appeared to play a role in the expression of
hearing loss. Other genetic or environmental factors are
likely to contribute to the development of hearing loss and
its characteristics in OI.
In an attempt to identify potential risk factors for the
development of hearing loss, patients’ histories of otitis
media, head injury or noise exposure were documented.
Despite the higher incidence of otitis media in the OI
population reported in the literature, which has been
hypothesized to follow from cranial molding and defor-
mities [17,25], a positive history of otitis media was not
associated with hearing loss as 73.7% of hearing-
impaired patients had not experienced any otitis media
episode. Still, about 90% of the OI subjects reporting
otitis media in childhood currently presented hearing
loss. Neither noise exposure nor head injury was found
to be associated with OI-related hearing loss. Head
injury or skull fractures were most often reported to
have occurred after the hearing loss onset and were also
noted in patients without hearing loss. Noise exposure
was reported in about 20% of patients with mixed hear-
ing loss and 5% of normal-hearing patients. Because
these risk factors were listed on the basis of personal
perception by the patients themselves, one may throw
doubt upon their relevance. Though, the risk to sustain
supplementary damage on hearing due to noise expo-
sure, head trauma or sequelae of otitis media should be
reduced to a minimum.
5. Conclusions
In this study among 184 Belgian, Dutch, and Italian OI
patients, hearing loss presents in 53% of patients and
the proportion of hearing-impaired patients rises with
increasing age. The predominant type of hearing loss is
a bilateral, symmetric, and progressive mixed hearing
loss. In a subsample of 114 OI patients with hearing
loss or older than 40 years, an attempt to link the audio-
logical phenotype with the underlying OI genotype is
performed. The manifestation, type or severity of hear-
ing loss correlates neither with the mutated gene nor
with the type I collagen defect or the location of the
mutation in the gene. Furthermore, identical mutations
are found to lead to considerable inter- and intrafamilial
variability in hearing pattern. However, in the present
study, inter- and intrafamilial comparisons of hearing
characteristics are limitated by the dissimilar age of the
subjects and relatives, while hearing loss characteristics
may evolve over time. Furthermore, in the majority of
the families included, not all affected relatives were
examined because they declined to participate or were
living abroad. Although history of otitis media, head
trauma, and noise exposure were more often reported in
the hearing-impaired OI patients, none of these poten-
tial risk factors were consistenly associated with the
occurrence of hearing loss. In conclusion, the mutation
causing OI is not sufficient for the expression of hearing
loss. Therefore, an additional genetic trigger is assumed
to be responsible for hearing loss in OI.
Additional material
Additional file 1: Audiological and molecular-genetic findings in the
selected sample of 114 osteogenesis imperfecta patients. The
hearing loss characteristics and results from molecular genetic tests in
114 individuals with osteogenesis imperfecta, grouped per family, are
presented. These data reflect inter- and intrafamilial variability in
audiological phenotype.
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